Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2023 | Role of platelet aggregation in dementia risk

Jaime Ramos Cejudo, PhD, New York University Grossman School of Medicine, New York, NY, shares new findings on the association of platelet aggregation to amyloid- and tau-PET in the Framingham Heart Study, a long-term multigenerational cohort study designed to analyze the factors that contribute to cardiovascular disease. By using light transmission aggregometry and inverse probability regression models, Prof. Ramos Cejudo and his team investigated whether platelet function and aggregation within middle age correlates with Alzheimer’s disease risk. Results after 20 years of follow-up indicated that platelet aggregation was independently and positively associated with dementia risk. In new work presented at AAIC, Prof. Ramos Cejudo demonstrated that platelet aggregation was not associated with amyloid- and tau-PET levels in the general population, but an association was seen in people receiving preventive platelet modifying treatment. Further work to understand the mediator role of platelet aggregation in the association between cardiovascular risk and Alzheimer’s disease is ongoing. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.